| Delineation of the exact transcription termination signal for type 3 polymerase III Z Gao, E Herrera-Carrillo, B Berkhout Molecular Therapy-Nucleic Acids 10, 36-44, 2018 | 97 | 2018 |
| Improving miRNA delivery by optimizing miRNA expression cassettes in diverse virus vectors E Herrera-Carrillo, YP Liu, B Berkhout Human gene therapy methods 28 (4), 177-190, 2017 | 85 | 2017 |
| Dicer-independent processing of small RNA duplexes: mechanistic insights and applications E Herrera-Carrillo, B Berkhout Nucleic acids research 45 (18), 10369-10379, 2017 | 83 | 2017 |
| Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA Z Gao, M Fan, AT Das, E Herrera-Carrillo, B Berkhout Nucleic Acids Research 48 (10), 5527-5539, 2020 | 69 | 2020 |
| Mutation of nucleotides around the+ 1 position of type 3 polymerase III promoters: The effect on transcriptional activity and start site usage Z Gao, A Harwig, B Berkhout, E Herrera-Carrillo Transcription 8 (5), 275-287, 2017 | 61 | 2017 |
| Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection E Herrera, S Tenckhoff, MJ Gómara, R Galatola, MJ Bleda, C Gil, G Ercilla, ... Journal of medicinal chemistry 53 (16), 6054-6063, 2010 | 59 | 2010 |
| SARS-CoV-2 evolution: on the sudden appearance of the omicron variant B Berkhout, E Herrera-Carrillo Journal of Virology 96 (7), e00090-22, 2022 | 54 | 2022 |
| RNA polymerase II activity of type 3 Pol III promoters Z Gao, E Herrera-Carrillo, B Berkhout Molecular Therapy-Nucleic Acids 12, 135-145, 2018 | 50 | 2018 |
| The impact of HIV-1 genetic diversity on CRISPR-Cas9 antiviral activity and viral escape G Darcis, CS Binda, B Klaver, E Herrera-Carrillo, B Berkhout, AT Das Viruses 11 (3), 255, 2019 | 44 | 2019 |
| Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity E Herrera-Carrillo, A Harwig, YP Liu, B Berkhout Rna 20 (9), 1410-1418, 2014 | 43 | 2014 |
| A single H1 promoter can drive both guide RNA and endonuclease expression in the CRISPR-Cas9 system Z Gao, E Herrera-Carrillo, B Berkhout Molecular Therapy-Nucleic Acids 14, 32-40, 2019 | 42 | 2019 |
| Bone marrow gene therapy for HIV/AIDS E Herrera-Carrillo, B Berkhout Viruses 7 (7), 3910-3936, 2015 | 38 | 2015 |
| Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide E Herrera, MJ Gomara, S Mazzini, E Ragg, I Haro The journal of physical chemistry B 113 (20), 7383-7391, 2009 | 38 | 2009 |
| Improvement of the CRISPR-Cpf1 system with ribozyme-processed crRNA Z Gao, E Herrera-Carrillo, B Berkhout RNA biology 15 (12), 1458-1467, 2018 | 32 | 2018 |
| The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy E Herrera-Carrillo, B Berkhout Gene therapy 22 (6), 485-495, 2015 | 32 | 2015 |
| Mechanistic insights on the Dicer-independent AGO2-mediated processing of AgoshRNAs YP Liu, M Karg, A Harwig, E Herrera-Carrillo, A Jongejan, A van Kampen, ... RNA biology 12 (1), 92-100, 2015 | 30 | 2015 |
| Attacking HIV-1 RNA versus DNA by sequence-specific approaches: RNAi versus CRISPR-Cas E Herrera-Carrillo, B Berkhout Biochemical Society transactions 44 (5), 1355-1365, 2016 | 26 | 2016 |
| CRISPR therapy towards an HIV cure E Herrera-Carrillo, Z Gao, B Berkhout Briefings in functional genomics 19 (3), 201-208, 2020 | 24 | 2020 |
| The influence of the 5΄-terminal nucleotide on AgoshRNA activity and biogenesis: importance of the polymerase III transcription initiation site E Herrera-Carrillo, Z Gao, A Harwig, MT Heemskerk, B Berkhout Nucleic acids research 45 (7), 4036-4050, 2017 | 22 | 2017 |
| The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS E Herrera-Carrillo, YP Liu, B Berkhout Molecular Therapy 22 (3), 596-606, 2014 | 21 | 2014 |
